Pfizer’s Phase III bladder cancer therapy trial meets primary endpoint
The trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...
Hosted on MSN38m
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
Pfizer PFE announced positive results from the phase III CREST study that evaluated its investigational PD-1 inhibitor ...
Pharmabiz9h
Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer
Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer: New York Monday, January 13, 2025, 13:00 Hrs [IST] ...
Pfizer’s Strategic Initiatives and Growth Prospects Drive Buy Rating
In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of ...
Reuters17h
United States
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...